Resources Repository
-
ArticlePublication 2012Modeling the Risks and Benefits of Depression Treatment for Children and Young Adults
This article, published in Value in Health, presents a discrete event simulation model to quantify …
This article, published in Value in Health, presents a discrete event simulation model to quantify the trade-offs with respect to clinical benefits and the risk of fatal and non-fatal suicidal behavior of alternative treatment strategies for a U.S. pediatric population with major depressive disorder. The authors evaluate treatment strategies including: selective serotonin reuptake inhibitors (SSRIs), cognitive behavioral therapy (CBT), and a combination of both. The results show that the use of SSRIs is associated with…
Microsimulation | Technology Assessment | Health/Medicine | North America | Mental Health | Health Outcomes -
ArticlePublication 2024Adopting Electric School Buses in the U.S.: Health & Climate Benefits
This article evaluates the health and climate benefits of replacing diesel school buses with electric …
This article evaluates the health and climate benefits of replacing diesel school buses with electric models in the U.S. Despite the high cost of electric buses, their benefits in reducing mortality and childhood asthma, as well as greenhouse gas emissions, could justify the investment. The study quantifies the benefits of replacing an average diesel bus with an electric bus, estimating $84,200 in total benefits per bus, with $40,400 from climate benefits and $43,800 from health…
Benefit-Cost Analysis | Health/Medicine | North America | Environmental Health | Government/Law -
ArticlePublication 2014Cost-Effectiveness of Second-Generation Antipsychotics for the Treatment of Schizophrenia
This article, published in Value in Health, describes a Markov model that compares the cost-effectiveness …
This article, published in Value in Health, describes a Markov model that compares the cost-effectiveness of alternate sequences of treatment strategies using second-generation antipsychotics (SGAs) for patients with schizophrenia. First-line treatments include one of the four SGAs: olanzapine (OLZ), risperidone (RSP), quetiapine (QTP), and ziprasidone (ZSD). Patients are able switch to another of these antipsychotics as second-line therapy, and only clozapine (CLZ) is allowed as third-line treatment. Model input parameters were obtained from the Clinical…
Cost-Effectiveness Analysis | Health/Medicine | North America | Mental Health | State-Transition